Table 3. Hemodynamic parameters in patients versus healthy controls.
| Patients (without DAA) | Controls | P-value | |
|---|---|---|---|
| MCA | |||
| N | 11 | 11 | |
| CBF (mL/100 g/min) | 34±5 | 36±11 | Ns |
| ASL CVR (%/10 mm Hg ▵EtCO2) | 44±20 | 53±10 | Ns |
| BOLD CVR (%/10 mm Hg ▵EtCO2) | 1.3±0.8 | 2.2±0.4 | <0.01 |
| OEF (%) | 41±8 | 38±6 | Ns |
| CMRO2 (μmol/100 g/min) | 116±39 | 111±40 | Ns |
| Patients (with and without DAA) | Controls | P-value | |
| MCA | |||
| N | 14 | 14 | |
| CBF (mL/100 g/min) | 32±6 | 38±12 | Ns |
| ASL CVR (%/10 mm Hg ▵EtCO2) | 45±18 | 52±10 | Ns |
| BOLD CVR (%/10 mm Hg ▵EtCO2) | 1.2±0.7 | 2.2±0.4 | <0.001 |
| OEF (%) | 39±8 | 39±6 | Ns |
| CMRO2 (μmol/100 g/min) | 106±39 | 120±47 | Ns |
Abbreviations: ASL CVR, arterial spin labeling cerebrovascular reactivity; BOLD, blood oxygenation level-dependent; CBF, cerebral blood flow; CMRO2, cerebral metabolic rate of oxygen; DAAs, delayed arrival artifacts; MCA, middle cerebral artery; OEF, oxygen extraction fraction.
Results obtained in patients versus controls (mean±s.d.) for the MCA territory (gray matter). Analysis was performed excluding and including patients with DAAs. P-values are shown in the table.